BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23294908)

  • 1. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
    Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
    BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial.
    Kim HY; Hsu PN; Barba M; Sulaiman W; Robertson D; Vlahos B; Khandker R; Nab H; Freundlich B; Koenig A
    Int J Rheum Dis; 2012 Apr; 15(2):188-96. PubMed ID: 22462423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
    Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
    J Rheumatol; 2013 Oct; 40(10):1658-68. PubMed ID: 23908446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
    van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
    Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
    Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
    Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.
    Kekow J; Moots RJ; Emery P; Durez P; Koenig A; Singh A; Pedersen R; Robertson D; Freundlich B; Sato R
    Ann Rheum Dis; 2010 Jan; 69(1):222-5. PubMed ID: 19293160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
    van Riel PL; Taggart AJ; Sany J; Gaubitz M; Nab HW; Pedersen R; Freundlich B; MacPeek D;
    Ann Rheum Dis; 2006 Nov; 65(11):1478-83. PubMed ID: 16464988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
    Pope JE; Haraoui B; Thorne JC; Vieira A; Poulin-Costello M; Keystone EC
    Ann Rheum Dis; 2014 Dec; 73(12):2144-51. PubMed ID: 23979914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept for the treatment of rheumatoid arthritis.
    Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
    Kameda H; Ueki Y; Saito K; Nagaoka S; Hidaka T; Atsumi T; Tsukano M; Kasama T; Shiozawa S; Tanaka Y; Takeuchi T;
    Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
    Nam JL; Villeneuve E; Hensor EM; Wakefield RJ; Conaghan PG; Green MJ; Gough A; Quinn M; Reece R; Cox SR; Buch MH; van der Heijde DM; Emery P
    Ann Rheum Dis; 2014 Jun; 73(6):1027-36. PubMed ID: 24618266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.
    Pavelka K; Szekanecz Z; Damjanov N; Majdan M; Nasonov E; Mazurov V; Fabo T; Bananis E; Jones H; Szumski A; Tang B; Kotak S; Koenig AS; Vasilescu R
    Clin Rheumatol; 2013 Sep; 32(9):1275-81. PubMed ID: 23666316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Zang C; Alvarez D; Fletcher T; Wajdula J; Yuasa H; Vlahos B
    Mod Rheumatol; 2013 Jul; 23(4):623-33. PubMed ID: 23011358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.